{"id":"W3083951977","doi":"10.1016/j.ccell.2020.08.007","title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial","year":2020,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":393,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; National Cancer Institute; Genentech; National Institutes of Health; Bristol-Myers Squibb Canada; Ono Pharmaceutical; Parker Institute for Cancer Immunotherapy; Breast Cancer Now; Exelixis; Meso Scale Diagnostics; Sanofi; Merck; Bayer Corporation; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Anthropological Association; Roche; Astellas Pharma US; Amgen; University of Texas MD Anderson Cancer Center; Pfizer","keywords":"Ipilimumab; Nivolumab; Prostate cancer; Medicine; Oncology; Internal medicine; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03752139322097603,"score_gpt":0.3103108764788775,"score_spread":0.2727894832579015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}